亿帆医药：F-652的ACLF适应症目前仍在临床策略论证中

Core Viewpoint - Yifan Pharmaceutical (002019) is currently in the clinical strategy validation phase for the ACLF indication of F-652, with no clear plans available at this time [1] Group 1 - Yifan Pharmaceutical responded to investor inquiries on an interactive platform regarding the status of F-652 [1] - The ACLF indication for F-652 is still under clinical strategy validation [1] - There are currently no definitive plans for the development of F-652 in the ACLF indication [1]